"Delayed Hematuria Common after Prostate Brachytherapy"
A significant proportion of patients with prostate cancer who are treated with brachytherapy develop gross hematuria years later, report researchers in BJU International. The findings come from a study of 20-year data collected for 2,454 men, aged a mean of 67 years, who received transperineal permanent prostate interstitial brachytherapy. Led by Michael Leapman from the Icahn School of Medicine at Mount Sinai, the team found that 218 (8.9 percent) of the men developed hematuria, over a mean period of 5.9 years, with 628 individual hematuria events identified. Learn more
Mount Sinai Study Finds Lung Cancer Surgery Safe for Many Patients Over 80
Apr 02, 2026 View All Press Releases
New Research Reveals Autism Risk Genes Are Shared Across Ancestries
Mar 30, 2026 View All Press Releases
Mount Sinai Study Advances “Social Music” as a Prescription for Better Health Outcomes
Mar 26, 2026 View All Press Releases